Shinji Kumagai
Senior Scientist JCR Pharmaceuticals Co Ltd
Shinji Kumagai received his M.S. from Waseda University and has over 20 years of experience in pharmaceutical R&D. He worked on oligonucleotide therapeutics at Osaka University before leading the introduction of the modality within Mitsubishi Tanabe Pharma, where he subsequently directed multiple drug discovery programs. Since joining JCR Pharmaceuticals in 2025, he has focused on advancing antibody-oligonucleotide conjugate (AOC) technologies for rare and neurological diseases.
Seminars
With BBB-penetrating technologies at the forefront of Korean innovation, the next frontier lies in moving beyond antibody shuttles to explore receptor‑mediated transcytosis for delivering therapeutic oligonucleotides to the brain. In this interactive workshop, explore the possibilities of platforms such as ABL Bio’s Grabody-B being utilized to shuttle ASOs and siRNAs across the BBB, and ponder questions such as:
- What do we understand about the behaviour of oligonucleotides when conjugated to antibodies and how can we optimize the conjugation for effective delivery?
- How can we overcome the challenge of siRNA negative charge limiting intracellular delivery in the CNS?
- How can we maximize endosomal escape of IV-administered oligonucleotides in the CNS?
- What are the advantages of delivering oligonucleotides via RMT vs intrathecal administration?
